IN SPITE of expanded anticoagulant therapy, new antihypertensive drugs, controversial anti-atherogenic regimens, and spectacular cardiovascular surgical treatment, it is apparent that we have not really solved the problem of thrombosis. It has been emphasized repeatedly that cardiovascular diseases are the most common cause of death at the present time. In the majority of cardiovascular deaths, the terminal event can be attributed to intravascular thrombosis. Necropsy evidence indicates that although atherosclerosis is the basic disease, final arterial occlusion by thrombosis is responsible for approximately 80 per cent of transmural myocardial infaretions. Similar evidence indicates that regional arterial thrombosis is responsible for 50 to 80 per cent of infarctions of the brain. Some cerebral and coronary occlusions, as well as arterial occlusions in many parts of the body, are caused by embolic detachments from thrombi formed in the heart itself. Patients still die of pulmonary embolism that starts as thrombosis in the peripheral veins. In addition to the lethal aspects of thrombosis, it is the cause of much serious disability from From the Mayo Foundation, Graduate School, University of Minnesota, Rochester, Minn. Presented at the meeting of the American Heart Association, Chicago, Ill., October 25 to 29, 1957. nonfatal cerebral stated that (ounmari ii therapy could l)e controlled satisfactorily and simply by determination of the (coagullsation time of whole blood. I would like to sounid a warning against substituting this test for the 1-stage determination of prothronmbbi time. In the first place, determination of the coagulation time of whole blood is sul)ject to mnaiiy errors and the results can be varied by small differences in technic. Even wheni the test is done carefully, if there is signiificant prolongation of the coagulation time it usually means that the effect of the anticoagulant has exceeded the therapeutic range as indicated by the 1-stage determinatioin of prothrombin time. Therefore, if the coagulation time of whole blood is used as a guide, the danger of bleeding will be increased.
Admittedly, anticoagulant therapy with the (oumarili compounds, with its implied necessity for multiple determinations of prothrombini time and the need for careful individualization of dosage schedules for each patient, lhas always been somewhat cumbersome and required time and experience on the part of the l)hysiciali for the securing of optimal results. Admittedly also, there has always been a desire for a simpler and safer method of producingt a similar type of anticoagulant effect. however, I doubt that, when the therapeutic principle of impairing blood coagulation is used to prevent thrombosis, it will ever be possible to simplify this type of treatment or to carry out such treatment without repeatedly checking the effect on the coagulability of the blood itself. Also, I doubt that any new coumnarin or indandione compound or other drug having similar effect will be developed that will be superior and easier to administer than are the compounds that are available at the present time. This should not preclude the search for a better, simpler. and safer antithrombotic therapeutic principle.
OTHER THERAPEUTIC CONSIDERATIONS Thrombolytic Agents. Although the basic mechanical structure of most thrombi is more complicated than that of simple blood clots, the solidifying element in both is fibrin. Since fibrin is a mesh produced by polymerization of the cigar-shaped molecules of fibrinogen, and since it is well established now that certain enzymes (fibrinolysins) destroy this mesh, it is a logical step to try to destroy fresh thrombi in blood vessels by these fibrinolytic agents. It is known that a fibrinolysin (plasmin) is present normally in the circulating blood, but that under most conditions it is kept in an inactive state by the presence of an antifibrinolysin.
In recent years research has been carried out in an attempt to produce thrombolysis by the introduction of 3 different types of fibrinolysins into the blood stream. A basic problem in this therapeutic approach has been to get the fibrinolysin into the blood stream in sufficient concentration without producing toxic effects and to get it in actual contact with the thrombus. 
